ADVISORY/FDA Approves Label Changes for VIOXX.Pharmaceutical Reporters ADVISORY...for Thurs. (April 11) WHITEHOUSE Whitehouse may refer to:
Attached please find a press release that Merck Merck may refer to:
abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of label changes for VIOXX Vi·oxx A trademark for the drug rofecoxib. Vioxx® Rofecoxib Pain management A COX-2 inhibitor used to manage osteoarthritic pain, acute pain in adults, primary dysmenorrhea. See COX-2 inhibitor. . The label changes include a new indication for VIOXX and data from the VIGOR study. Merck will host a conference call for pharmaceutical industry analysts from 4:00 to 4:45 p.m., EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT , to discuss this announcement. The news media is invited to call in on a listen-only mode. Following this call, a Q&A session for the media will be held from 5:00 to 5:45 p.m. The dial-in number for the 4:00 analyst conference call is (973) 321-1020. The dial-in number for the 5:00 news media Q&A session is (973) 872-3100. The analyst conference call will be simultaneously webcast on www.merck.com. If you are unable to listen to the either call, the replay numbers are: Analyst conference call: (402) 998-0193 News media Q&A session: (973) 341-3080/ (PIN: 3225271) The replay numbers and the webcast will be active for one week. Please feel free to call me with any questions. Gregory E. Reaves Senior Director, Media Relations 908/423-6022 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion